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Inflammatory bowel disease (IBD) is a condition of the intestine with significant morbidity. Although hereditary, environmental, immunologic, and bacterial factors have been implicated, the
etiology of IBD remains unknown. Since opioid peptides modulate inflammatory cytokine production and opioid antagonists promote tissue growth and repair, we hypothesized the opioid antagonist naltrexone could reduce inflammation of the bowel. Using a
chemically-induced mouse model of IBD, C57BL/6J mice received
either untreated drinking water or water containing 2% dextran
sulfate sodium (DSS) in two parallel regimens modeling moderate and severe colitis. After colitis was established, animals in the
moderate colitis study were administered either saline (control) or
naltrexone (NTX; 8 or 400 µg/kg) daily, while those in the severe
colitis study received 0.1 or 10 mg/kg NTX. DSS-treated animals
had significant weight loss ( p = 0.006) and higher disease activity index (DAI) scores ( p < 0.001) compared to water controls.
However, NTX treatment of mice with moderate colitis resulted in
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less weight loss, lower DAI scores, and less histologic evidence of
inflammation compared to controls. Significantly, elevated levels
of colonic RNA for pro-inflammatory cytokines interleukin (IL)-6
and IL-12 were also decreased toward normal with NTX. Similar
to patients with severe and unresponsive disease, animals in the severe colitis study did not significantly respond to treatment. Thus,
NTX therapy reverses physical symptoms, histologic evidence, and
molecular markers of inflammation in moderate colitis. The mechanism by which NTX acts to reverse colitis is related in part to the
decreased expression of pro-inflammatory cytokines.
Keywords

Naltrexone, inflammatory bowel disease, opioids,
antagonists

INTRODUCTION
Inflammatory bowel disease (IBD) includes two idiopathic
conditions termed ulcerative colitis and Crohn’s disease which
affect approximately 1 million people in North America
(Cominelli, 2004). The pathogenesis of IBD appears to involve the dysregulation of the immune system in the intestine in response to either commensal bacteria or environment
in a genetically predisposed host (Cominelli, 2004; Sands,
2007). Cytokines have been implicated in the pathogenesis of
Crohn’s disease, in particular the pro-inflammatory/TH 1 cytokines interleukin-1 (IL-1), IL-2, IL-6, IL-12, IL-18, interferon
(INF)-γ , and tumor necrosis factor-alpha (TNFα) (Pizarro and
Cominelli, 2007).
Medical treatment of this condition has focused on targeting the inflammatory response with immunosuppressive drugs
(i.e., corticosteroids, azathioprine) or immune-specific biological drugs, such as monoclonal antibodies against TNFα (Targan
et al., 1997; Sandborn and Hanauer, 1999; Hanauer and Present,
2003; Navarro and Hanauer, 2003; Bell and Kamm, 2000;
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Kamm, 2006). Unfortunately, chronic immunosuppression may
increase the risk of developing infections such as tuberculosis
(Keane et al., 2001) and lymphoma (Kandiel et al., 2005). Since
the risks may at times outweigh the benefits when immunomodulating drugs are combined with biologic agents (Hanauer, 2007),
novel therapeutic approaches to treat IBD are needed.
Accumulating evidence points to roles for endogenous opioid peptides in the development or perpetuation of inflammation. Immune cells have been shown to express µ, κ, and δopioid receptors that bind both opioid agonists and antagonists
(McCarthy et al., 2001). In vivo treatments with opioids have
been shown to induce the release of pro-inflammatory cytokines,
such as IL-12 and TNFα, by mouse peritoneal macrophages
(Tomassini et al., 2003). Studies have verified similar roles
with endogenous opioids, demonstrating that opioids, including
[Met5 ]-enkephalin, stimulate peritoneal macrophages in rodents
systems (Vujic et al., 2004). Opioid receptors are found throughout the gastrointestinal tract in the myenteric and submucosal
plexus as well as in epithelial cells (Jimenez et al., 2006).
Furthermore, in these studies, cytokine production was decreased by simultaneous treatment with the opioid receptor antagonist, naltrexone, indicating the effects were mediated by
opioid receptors expressed by peripheral and intestinal immune
cells. Pre-treatment with naltrexone (10 mg/kg) has also been
shown to block TNFα synthesis and induction of septic shock
in LPS/D-galactosamine-treated mice (Greeneltch et al., 2004).
Recently, a clinical study in human subjects with active Crohn’s
disease demonstrated that naltrexone therapy improved Crohn’s
inflammatory scores and quality of life (Smith et al., 2007).
Given the role of endogenous opioids in inflammation and
the inhibition of these effects by the opioid receptor antagonist,
naltrexone, we hypothesized that naltrexone therapy could improve colitis in mice. In order to test this hypothesis we used
the DSS (dextran sulfate sodium) model of experimental colitis in mice to examine symptoms, tissue histology, and RNA
profiling of cytokines in response to naltrexone. The addition of
DSS to the drinking water induces hematochezia, weight loss,
intestinal shortening, and infiltration of neutrophils, and thus
serves as a model for human inflammatory bowel diseases, particularly ulcerative colitis (Okayasu et al., 1990). Breakdown
of epithelial barrier function in DSS-treated mice leads to an
induction of pro-inflammatory cytokines, which are thought to
play a central role in disease progression (Strober et al., 2002).
Treatments aimed at reducing this excessive inflammatory response have demonstrated therapeutic promise in DSS models;
therefore, DSS-treated mice are particularly suitable for proofof-concept studies of novel IBD therapeutics and treatments that
may reduce the cytokine-induced inflammatory state (Pizarro
et al., 2003).
METHODS
Animals and Experimental Procedures
Two separate studies were performed to test the effects of
naltrexone: chemically induced moderate or severe colitis. The

research protocol was approved by the Institutional Animal Care
and Usage Committee of the Pennsylvania State University College of Medicine and animals were housed in accordance with
the AAACCR guidelines for veterinary medicine.
In the moderate colitis study, 6- to 8-wk-old male C57BL/6J
mice (Charles River, Wilmington, MA) were randomly allocated into one of two groups of 24 mice each. Food and water were provided ad libitum. Individual mice were housed
in separate cages for accurate measurement of food and water intake to determine whether NTX alone affected animal
weight, water intake, and food consumption, each measured
daily. The first group (Normal) received untreated drinking water and the second group (DSS) received water containing 2%
dextran sulfate sodium (DSS; TDB Consultancy AB, Uppsala,
Sweden; molecular weight, 40,000) for six days followed by untreated water for three additional days (See treatment schedule,
Figure 1A).
Mice in each group (Normal or DSS) were randomly subdivided into three treatment groups of 8 mice each. Starting on Day
3, mice were treated once daily for six consecutive days with
a subcutaneous (SC) injection (0.1 ml) of one of the following: saline (control), 8.0 µg/kg naltrexone (NTX), or 400 µg/kg
NTX. These doses were selected to bracket the approximate
clinical dosing reported with efficacy in humans with Crohn’s
disease (Smith et al. 2007). On Day 9, all animals were necropsied and their colons resected and analyzed.
In the severe colitis study, C57BL/6J mice were placed into
one of four groups of 10 mice each. The first group received
normal water (control). The remaining groups received water
containing 2% DSS (30 mice) for the duration of the study (9
days). Beginning on Day 3, the normal water mice and 10 of
the DSS-treated mice were injected with vehicle (water; 0.1
ml SC daily). For NTX treatment in this study, an intermediate dose (100 µg/kg NTX) and an escalated dose (10 mg/kg
NTX) were used to test efficacy against the more severe symptoms anticipated with extended DSS treatment. Mice were injected (0.1 mg/kg or 10 mg/kg; 0.1 ml SC daily; n = 10) until
the end of the experiment on Day 9 (See treatment schedule,
Figure 2B).
The colitis disease activity index (DAI) was calculated for
each mouse according to the system established by Murthy and
colleagues (1993) using animal weight, stool occult blood, and
stool consistency. Overt changes in stool consistency were rarely
discerned in the moderate colitis study so a modified DAI was
calculated based on percent weight loss and stool hemoccult or
presence of gross bleeding.
Histologic Evaluation
At necropsy, the entire colon was excised, measured in length,
and bisected into proximal and distal portions. The proximal
and distal colons were additionally divided for RNA extraction and histology. Each histology specimen was fixed in 10%
neutral buffered formalin, paraffin embedded and sectioned
for hematoxylin and eosin (H&E) staining. Specimens were
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FIG. 1. Daily weight, food and water consumption. (A) Mean weight (expressed as % starting weight ± SEM) of animals receiving either normal drinking water
(upper panel) or 2% DSS in drinking water (lower panel) is shown. DSS-induced weight loss was lessened by treatment with naltrexone (NTX) in moderate colitis
by Day 6. (B) Mean daily food intake in grams per mouse and (C) total water intake in ml per mouse over the 9-day course of study is shown. Asterisks indicate
significantly different values between corresponding DSS and Normal (No DSS) treatment groups (* p < 0.025; ** p < 0.005). Significant differences in water
intake between saline- and 8 µg/kg NTX-treated mice are indicated by a † ( p = 0.022).

examined microscopically and scored based upon the criteria
established by Williams et al. (2001) by an investigator blinded
to the treatment groups. Briefly, a representative longitudinal
section from each mouse was scored at six random fields for
inflammation severity, extent of inflammation (mucosa, submucosa, transmural) and crypt damage. Each of these scores
was weighted to reflect the percent involvement of the overall section and the weighted scores from each of the six fields
were averaged to achieve an overall inflammation score for each
mouse.
Statistical Analysis
Results were calculated as mean ± SEM. To eliminate undo
influence of abnormally sick or resistant mice, statistical outliers from normally distributed data in weight loss and histological sectioning were determined (Minitab 13, State College, PA; below Q1 – 1.5×IQR, above Q3 + 1.5×IQR) and
excluded. Pairwise Student t-tests were performed (Minitab
13) using a modified Bonferroni method to correct for mul-

tiple comparisons to controls. Statistical comparisons were
performed between NTX treatment sub-groups and their corresponding vehicle control, as well as between the Normal
and DSS groups, comparing corresponding vehicle or NTX
treatments.
Quantitative Real-Time PCR
Total RNA was extracted from the distal colon samples (Trizol; Invitrogen, Carlsbad, CA) and subjected to analysis by RealTime RT-PCR. RNA (18S and 28S bands) was visualized using
the Agilent 2100 Bioanalyzer (Agilent Technologies) and concentrations were adjusted. First strand cDNA was then produced
from 1.0 µg of total RNA using random hexamer primers and
the SuperScript III Reverse Transcription kit (Invitrogen). The
concentration and quality of resulting cDNA was quantified and
analyzed using the Agilent 2100 Bioanalyzer or spectroscopically with the NanoDrop ND-1000 (NanoDrop Technologies,
Wilmington, DE). Samples were standardized to 30 ng/µl, and
60 ng of cDNA per sample was then utilized as a template
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FIG. 2. Naltrexone treatment reduces Disease Activity Index (DAI) scores. Mice that received normal drinking water (saline or NTX-treated) showed no evidence
of colitis by DAI score (A, upper panel; mean ± SEM). DAI scores increased over time in both the moderate (A, lower panel) and the severe colitis (B) studies.
Treatment with 400 µg/kg NTX significantly lowered DAI scores in moderate colitis on Day 6 († p = 0.015). In contrast, NTX failed to improve DAI scores of
the severe colitis model (B).

for Real-Time RT-PCR using a SYBR Green Master Mix (Qiagen, Valencia, CA). 18S rRNA primers (Eurogentec, San
Diego, CA) and the following gene-specific primer sequences
obtained from PrimerBank (Wang and Seed, 2003) were utilized: β-actin, 6671509a; IL-5, 6754336a; IL-6, 13642311a; IL12, 6680395a; STAT3, 13277852a; STAT4, 6755670a; Muc2,
3452503a2; TFF3, 6755773a1; Palladin, 9828173a1; TGF-β
BP, 7305243a1; and, TNFα, 202093a3. To exclude the possibility of genomic DNA contamination, control reactions with
no cDNA template were also performed for each gene-specific
primer set. PCR amplification and analysis were performed with
the Applied Biosystems Sequence Detection System 7300 using the Relative Quantification (ddCt) Plate setup. At least six
replicates were performed for each target gene set. Amplification data for the target genes were calibrated using the 18S
rRNA endogenous control within each sample. The resulting
mean CT values were then normalized to the β-actin expression (corresponding treatment groups) to ensure observed differences were biologically robust. Pairwise Student t-tests were
performed on the normalized mean CT values for each group
using a modified Bonferroni method to correct for multiple
comparisons.

RESULTS
Effects of Naltrexone on Animal Weight, Food and Water
Consumption
Over the 9-day course of the moderate colitis study, Normal
control animals given untreated drinking water exhibited steady
weight gain (Figure 1A, upper panel) while DSS mice showed
weight loss beginning between Days 4 and 6 (Figure 1A, lower
panel) and continuing until necropsy (Day 9). Animals treated
with naltrexone exhibited less weight loss compared to DSS
+ saline mice, reaching statistical significance on Day 6 ( p =
0.02). NTX-treated mice also had a tendency toward decreased
weight loss on Days 7 and 8, although they did not reach statistical significance.
Food consumption was significantly decreased in the animals
with DSS-induced colitis compared to animals without colitis
(Figure 1B). Naltrexone treatment alone had no effect on food
consumption in both normal animals and DSS-treated animals.
Animals treated with NTX (8 µg/kg) had slightly decreased water consumption (Figure 1C). DSS-treated mice drank less water
that their treatment counterpart, but there was no difference
between the DSS groups treated with saline or NTX (Figure 1C).
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Disease Activity Index (DAI) Scores are Reduced by
Naltrexone Treatment
To monitor disease progression, a disease activity index
(DAI) was assessed daily for each mouse including weight and
stool hemoccult. DAI scores for all Normal mice (no DSS),
regardless of saline or NTX treatment, showed no clinical evidence of colitis (Figure 2A, upper panel), suggesting that NTX
alone has no deleterious effects on the colon. All DSS-treated
mice developed colitis symptoms (hemoccult-positive stools and
increased DAI scores) by Day 4, which continued to increase
through the end of each study (moderate colitis, Figure 2A lower
panel; severe colitis, Figure 2B). A reduction in the DAI scores
was evident with NTX treatment in animals with moderate colitis; on Day 6, DSS + 400 µg/kg NTX animals had significantly
lower (55%) DAI scores than DSS + saline mice ( p = 0.015).
DAI scores for 400 µg/kg NTX mice at Day 7 were also improved, but did not reach significance ( p = 0.038). In contrast,
neither dose of NTX (0.1 mg/kg or 10 mg/kg) improved the DAI
score in severe colitis (Figure 2B).
Colon Length
Reduced colon length, another indicator of colitis, was also
evident in all DSS-treated animals. In the moderate colitis study,
control mice drinking normal water and injected with saline had
colon length 26% longer than DSS-treated animals (9.32 ± 0.39
cm vs. 6.95 ± 0.43 cm, respectively; p = 0.002). DSS-mice
treated with naltrexone had more typical colon lengths (7.86 ±
0.31 cm; p = 0.1), although they were still 15% shorter than in
the Normal (no DSS) animals.
Histological Evidence for Reduced Colonic Inflammation
in Naltrexone-Treated Mice
Histologic inflammation scores and H&E stains of the distal
colon in untreated and treated animals are shown in Figure 3. No
inflammation was observed in control animals drinking normal
water (saline or NTX-treated), indicating that naltrexone alone
did not alter the mucosal integrity of the colon (Figure 3A). All
DSS animals had increased inflammation scores, and exhibited
crypt damage and increased leukocyte infiltration. In moderate
colitis (Figures 3A and 3B), the DSS + NTX animals had a
significant decrease in inflammation and damage. The DSS +
400 µg/kg NTX treated mice had reduced histology scores ( p =
0.018; Figure 3A), with improved crypt architecture and fewer
invading leukocytes than were observed in the DSS + saline
mice (Figure 3B).
Animals with severe colitis had no improvement in their histology scores with NTX. Although those mice treated with the
lower dose of NTX (0.1 mg/kg) had less inflammation than
saline-treated mice and high-dose NTX (10 mg/kg) mice, this
difference was not statistically significant (Figure 3C and 3D).
No histologic changes consistent with colitis were observed
in the proximal colons of the mice (data not shown).
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Expression of DSS-Induced, Pro-inflammatory Cytokine
Genes is Decreased by Naltrexone Treatment
Because naltrexone reduced the inflammatory histology of
DSS-induced colitis, the expression of several genes of interest, including both cytokines and downstream mediators, was
examined by Real-Time RT-PCR. Expression of β-actin, cytokines IL-5, IL-6, IL-12, and transcription factors STAT3 and
STAT4 were assessed using 18S rRNA as an endogenous control.
After normalizing to β-actin, IL-5 levels were not significantly
changed by either DSS + saline or by DSS + NTX (Figure
4A). Similarly, levels of TNFα were not significantly changed
in DSS-treated animals compared to normal, uninflamed tissue
(data not shown). Because TNFα is an early mediator of inflammation, transcript levels may have already subsided during the
post-DSS recovery that preceded necropsy.
By contrast, mRNA encoding the cytokines IL-6 and IL-12,
known to be up-regulated in IBD, were increased in DSS +
saline animals in comparison to Normal controls (Figures 4B
and 4C). The increase in IL-6 mRNA was 66-fold, while the
increase in IL-12 was more modest (2.7-fold). Upon treatment
with naltrexone, levels of IL-6 and IL-12 were reduced and, for
IL-12, naltrexone treatment restored mRNA expression to that
seen in the colitis-free, Normal mice. The reduction in IL-6 was
also significant, although levels were not completely restored to
those seen in the colitis-free animals.
The mRNA for cytokine signaling intermediates STAT3,
downstream of IL-6, and STAT4, downstream of IL-12 (Mudter
et al., 2005), also were increased in DSS + saline animals
(2.20- and 8.03-fold, respectively) (Figures 4B and 4C). However, STAT3 and STAT4 mRNA levels were not decreased to
as great an extent by naltrexone treatment. This may reflect
the fact that STAT 3 and STAT4 activities are regulated both
at the level of transcription and post-transcriptionally by phosphorylation and nuclear relocalization in response to cytokine
signaling (Mudter et al., 2005). In the severe colitis study, inflammatory cytokine markers, as measured by Real-Time RT-PCR,
were also significantly elevated by DSS treatment. However,
in these animals exhibiting severe, rather than moderate colitis,
neither NTX dose significantly affected RNA levels (data not
shown).
DISCUSSION
This study is the first to report improvement of colitis in a
murine model upon treatment with an opioid antagonist. In both
the moderate and severe colitis studies, we administered DSS for
three days prior to either vehicle or naltrexone injections, emulating a condition of established bowel inflammation preceding
treatment. Naltrexone treatment resulted in a rapid mitigation of
moderate colitis symptoms in DSS mice, including weight loss
and bleeding. Furthermore, the modest differences in histology
(DSS ± NTX) may have been even greater if the diseased animals were not allowed potential time for recovery (post-DSS)
prior to necropsy.
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FIG. 3. Histologic scores are improved in moderate colitis mice treated with naltrexone. At necropsy, longitudinal sections of the distal colon were H&E stained
and evaluated using the scoring system of Williams and colleagues (2001). Histology scores are expressed as the mean ± SEM. Normal histology was observed
in animals drinking untreated water compared to high inflammatory scores in DSS-treated animals (A). Naltrexone treatment improved the histologic scores in
animals with moderate colitis (A). Representative H&E sections of distal colon from animals with moderate colitis are shown in B. Compared to the normal
appearance of healthy murine colon (Normal + saline; top), leukocyte infiltration and an absence of normal crypt architecture are evident in the DSS + saline mice
(middle). Improved architecture and less inflammation are clearly discernable in DSS mice treated with 400 µg/kg NTX (bottom). Cross indicates significantly
different values between DSS + saline and DSS + 400 µg/kg NTX ( p = 0.018). In contrast, NTX was unable to reverse the inflammatory response observed in
the severe colitis model (C, D).

A robust, impact on pro-inflammatory gene expression by
naltrexone was also confirmed. Characteristic of IBD, significant elevations in the gene expression of IL-6 and IL-12 cytokines were induced with DSS. However, naltrexone treatment

significantly decreased their expression in DSS mice to normal or near-normal levels. This suggests a possible pathway by
which NTX improves colitis. Pro-inflammatory NF-κB signaling is associated with opioid receptor activity in immune cells
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FIG. 4. Gene expression of DSS-induced pro-inflammatory cytokines is decreased by naltrexone. Relative mRNA levels for (A) beta-actin and the cytokine IL-5;
(B) cytokine IL-12 and downstream mediator STAT4; and (C) cytokine IL-6 and downstream mediator STAT3, were determined by Real-time RT-PCR using total
RNA from the distal colon. Target genes were calibrated to 18S rRNA, and means were normalized to beta-actin expression for each corresponding treatment group.
Histogram columns represent the mean relative quantity (RQ = 2−CT ) and bars represent a 95% confidence interval (CI; RQ = 2−(CT±CI) ). DSS induced
significant elevations in the RNA of pro-inflammatory cytokines IL-6 and IL-12. However, mice treated with naltrexone exhibited restoration toward normal levels.
Asterisks indicate significantly different values between corresponding Normal + saline and each DSS treatment group (* p < 0.0008). Significant differences
between DSS-Saline and DSS-NTX mice are indicated by a † (IL-12, p < 0.005; STAT4, p < 0.024; IL-6, p < 0.0008).

(Chen et al., 2006). When opioid receptor signaling is blocked
by naltrexone, the over-stimulation of immune system is moderated, cytokine levels are restored, and a more normal mucosal
structure reappears.
There is ample evidence that opioid peptides, particularly
delta opioid receptor agonists, can regulate immune responses
(House et al., 1996). First, immune cells secrete opioid peptides (Cabot, 2001; McCarthy et al., 2001) and activation of
murine T-lymphocytes increases the synthesis and secretion of
[Met5 ]-enkephalin (Zurawski et al., 1986). Second, immune
cells express delta, mu, and kappa opioid receptors that respond
to endogenous and synthetic opioids (Cabot, 2001; McCarthy
et al., 2001). In fact, [Met5 ]-enkephalin knock-out mice exhibit

a defect in T-lymphocyte activation and a reduced ability of Tlymphocytes to proliferate (Hook et al., 2003).
Both endogenous and exogenous opioids have been shown
to intensify the production of pro-inflammatory cytokines by
immune cells and, in some cases, this opioid-stimulated increase in cytokines has been abrogated by opioid receptor antagonists (Vujic et al., 2004). Third, while opioid peptides do not,
in themselves, induce inflammatory responses, they can sensitize T-lymphocytes and macrophages to other pro-inflammatory
stimuli (Hucklebridge et al., 1990; Kamphuis et al., 1998).
Thus, because opioids can enhance the immune response to proinflammatory stimuli and thereby contribute to the escalation of
inflammation, it is reasonable to suggest that naltrexone’s action
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on both T-lymphocytes and macrophages could effectively moderate the excessive pro-inflammatory response in IBD. Consistent with this notion, the DSS-induced pro-inflammatory response in this study was down-regulated by opioid receptor
blockade.
Although naltrexone is a competitive antagonist at delta, mu
and kappa opioid receptors, the effects on immune function reported herein are consistent with delta receptor blockade. In
a broad sense, while delta opioid receptor stimulation is proinflammatory, signaling through mu opioid receptors has been
shown to be immunosuppressive (McCarthy et al., 2001). Indeed, the use of specific mu receptor agonists for treatment of
IBD has shown therapeutic benefit both in mouse models and
in human mucosal explants (Philippe et al., 2003, 2006). Studies with delta and mu receptor-specific antagonists will further
clarify the role of these receptors in colonic inflammation. Conceivably, a delta receptor antagonist and mu receptor agonist
may function synergistically with maximal therapeutic benefit.
It has yet to be determined whether naltrexone blocks an overactive opioid peptide system which is aggravating the inflammatory response, or whether it augments the release of endogenous
opioids to alter diarrhea and pain through specific receptors in
the gut. In addition to inflammatory modulation, naltrexone may
elicit other complementary effects, potentially mediated through
blockade of a second type of opioid receptor, the opioid growth
factor (OGF) receptor. [Met5 ]-enkephalin binding to the OGF receptor generally inhibits growth and repair. Naltrexone blockade
of the receptor, which is expressed throughout the gastrointestinal tract, has been shown to promote cell proliferation and reepithelialization in esophageal epithelium (Zagon et al., 1997).
As evidenced by the improved histology scores, healing of the
gastrointestinal mucosa observed in our studies may be the result of the simultaneous effects of naltrexone on inflammation
and epithelial renewal.
Current therapies for IBD that target pro-inflammatory cytokines (i.e., anti-TNFα monoclonal antibodies) eliminate the
cytokines and carry an increased risk of infection due to immune suppression (Sandborn and Targan, 2002; Hanauer, 2007).
Humanized monoclonal antibodies also show diminished efficacy over time and have significant secondary complications,
decreasing their suitability for long-term use. Because opioid
receptor blockade down-regulates, but does not eliminate, proinflammatory cytokines, naltrexone therapy may have fewer undesirable side-effects than currently-used agents. Additionally,
the versatility of naltrexone for oral administration presents advantages in patient compliance.
Our results also support our previous clinical report of efficacy with low-dose naltrexone. A low-dose of naltrexone (4.5
mg), was shown to decrease inflammation in human subjects
with Crohn’s disease (Smith et al., 2007). In the moderate colitis
study presented here, naltrexone was effective in microgram per
kilogram doses. In the severe colitis portion, the lower dose (0.1
mg/kg) exhibited a trend toward improvement, while high-dose
(10 mg/kg) showed no effect, although both treatments were

arguably complicated by the induction of more severe colitis
than in the moderate study. This reflects current care for patients
with severe colitis, in which the inflammation at times exceeds
medical management, necessitating surgery. While naltrexone
has been approved by the Food and Drug Administration for
alcohol withdrawal syndromes (Petrakis et al., 2007) at a dose
of 50 mg daily, it is unknown how this higher dose affects inflammatory responses and cytokines.
Precedence for greater efficacy of low-dose therapies already exists. Others have shown that micromolar concentrations
of dextromethorphan, a D-isomer of the codeine analog levorphanol, induces a neuroprotective effect in the brain by suppression of proinflammatory factors superoxide, NO and TNFα (Liu
et al., 2003, 2005). This inhibitory effect on free radical generation by ultra-low concentrations of dynorphins is shared by
another opioid peptide, enkephalin (Zaitsev et al., 1991; Efanov
et al., 1994), where femtomolar concentrations of an enkephalin
analog inhibited the reactive burst from human neutrophils and
mouse macrophages. Thus manipulating the opioid-opioid receptor axis with small doses of these compounds plays a role in
modulating inflammatory mechanisms.
These data demonstrate a role of endogenous opioids in the
development and progression of IBD and the effectiveness of
opioid receptor blockade in reducing of colonic inflammation
and damage. On the whole-animal, tissue, and molecular levels, naltrexone treatment alleviated the effects of DSS-induced
colitis. Further work will more specifically define the role of
endogenous opioids in IBD, the mechanisms linking opioid receptor activation and cytokine production, and the therapeutic
potential of naltrexone or other opioid antagonists for the treatment of IBD.
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